Hepatitis C Antiviral Resistance in African-Americans

ClinicalTrials.gov ID: NCT00038974

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00038974. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.

Study identification

NCT ID: NCT00038974
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Enrollment: 401 participants

Conditions and interventions

Conditions

Hepatitis C

Interventions

peginterferon alfa-2a Drug
Ribavirin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2002 (Type not available)
Primary completion: Dec 2004 (Actual)
Completion: Nov 2005 (Actual)
Last update posted: Aug 3, 2017

2002 – 2005

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California, San Francisco	San Francisco	California	94143	—
University of Miami School of Medicine	Miami	Florida	33136	—
Rush University	Chicago	Illinois	60612	—
University of Maryland School of Medicine	Baltimore	Maryland	21201	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
University of Michigan Medical Center	Ann Arbor	Michigan	48109	—
New York-Presbyterian Medical Center	New York	New York	10032	—
University of North Carolina	Chapel Hill	North Carolina	27599	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00038974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 3, 2017 · Synced Nov 14, 2026